Very complex, promising research is currently underway to use humanized bispecific single-domain antibodies (bsVHH). But, unfortunately, harnessing the immune system can get very complicated. This article introduces an experimental antibody with a novel approach to fighting CLL/SLL.
Our immune system is a complex organization of lymphocytes, myeloid cells (granulocytes, macrophages, dendritic cells), complement factors, cytokines, and other chemical mediators, which all work together to fend off disease and infection.
These results are encouraging and show that patients with relapsed/refractory B-cell NHL treated with bispecific LV20.19 CAR T-cells have a high overall response rate and low rates of grade ≥3 CRS or ICANS.
In this study presented at the American Society of Hematology Annual Meeting and Exhibition (ASH 2021), the authors evaluated the effectiveness of triple gene-modified cells, called “iDuo” Natural Killer (NK) cells. Dr. Alex Danilov interviews Dr. Veronika Bachanova, MD, Professor of Medicine and Director of Cell Therapies and Hematologic
The short answer is that it is certainly beginning to look that way for a lucky few. This month celebrated the 10th CAR-T anniversary of Doug Olson, who remains cancer-free with persistent CAR-T cells that still play WHACK-A-MOLE should any cancerous CLL cells dare to reappear.
CLL Society brings ASH 2021 to you! The American Society of Hematology Annual Meeting had important research presented and now Drs. Anthony Mato and Brian Koffman will highlight findings that you should know when considering future treatment options.
CAR-T therapy is a revolutionary therapy that trains the patient’s own cells to attack their CLL/SLL. The science can be somewhat complicated and advanced, but the results can be amazing. You can learn more about CAR-T therapy in this easy-to-understand CAR-T brochure that can be viewed in this digital flipbook format